Universidad de Guadalajara, Guadalajara, Jalisco, México.
Rheumatol Int. 2011 Aug;31(8):1065-8. doi: 10.1007/s00296-010-1391-8. Epub 2010 Mar 24.
The objective of this study is to establish whether there is an association between the presence of FCGR3A V(176) polymorphism with SLE or its manifestations. We included 94 patients according to the 1982 ACR criteria as well as 98 controls matched by age and gender. The 11 ACR diagnostic criteria were analyzed on the clinical files. The polymorphism FCGR3A V(176) was determined by direct sequencing. There was not an association between the polymorphism FCGR3A V(176) with SLE or its main manifestations. The allelic frequency for F(176) was: 0.80 and 0.72 in cases and controls, respectively (P = 0.09, IC95%: 0.42-1.07); and the genotypic frequency in the group of cases was: 0.65 for homozygotes F(176)/F(176), 0.30 for heterozygotes and 0.05 for the homozygotes V(176)/V(176), while for the control group it was 0.53, 0.39 and 0.08, respectively. The polymorphism FCGR3A V(176) is not associated with SLE or any of its manifestations in patients with SLE from the West of Mexico.
本研究旨在确定 FCGR3A V(176) 多态性与 SLE 或其表现之间是否存在关联。我们纳入了 94 名符合 1982 年 ACR 标准的患者和 98 名年龄和性别匹配的对照者。临床档案分析了 11 项 ACR 诊断标准。通过直接测序确定 FCGR3A V(176) 多态性。FCGR3A V(176) 多态性与 SLE 或其主要表现之间没有关联。F(176)的等位基因频率分别为：病例组为 0.80，对照组为 0.72（P=0.09，95%CI：0.42-1.07）；病例组的基因型频率为：纯合子 F(176)/F(176)为 0.65，杂合子为 0.30，纯合子 V(176)/V(176)为 0.05，而对照组分别为 0.53、0.39 和 0.08。在来自墨西哥西部的 SLE 患者中，FCGR3A V(176) 多态性与 SLE 或其任何表现均无关联。
